Inventor · disambiguated record
Timothy A. Lewis
Also filed as: LEWIS TIMOTHY · LEWIS TIMOTHY A
20 granted patents·10 pending applications·58 citations·filing 2000–2025
93Inventor score
Top patents by PatentIndex Score
30 records- 0194US11773070B2DihydrooxadiazinonesBAYER AG·Filed 2022·Granted Oct 3, 2023·2 cites·9 claims
- 0291US11325913B2Compounds and methods for the treatment of malariaBROAD INST INC·Filed 2020·Granted May 10, 2022·3 cites·20 claims
- 0390US12258323B2DihydrooxadiazinonesBAYER AG·Filed 2022·Granted Mar 25, 2025·1 cites·15 claims
- 0490US11427553B2DihydrooxadiazinonesBAYER AG·Filed 2018·Granted Aug 30, 2022·4 cites·11 claims
- 0588US11142522B2Compounds, compositions and methods for cancer treatmentBROAD INST INC·Filed 2018·Granted Oct 12, 2021·4 cites·16 claims
- 0684US10738055B2Compounds and methods for the treatment of malariaBROAD INST INC·Filed 2018·Granted Aug 11, 2020·3 cites·18 claims
- 0783US2024366620A1Compounds, compositions and methods for cancer patient stratification and cancer treatmentBayer Pharma AG·Filed 2024·Application pending·0 cites
- 0881US9890127B2Compounds and compositions for the treatment of cancerBROAD INST INC·Filed 2014·Granted Feb 13, 2018·3 cites·12 claims
- 0980US10059711B2Compounds and methods for the treatment of malariaBROAD INST INC·Filed 2014·Granted Aug 28, 2018·5 cites·14 claims
- 1080US6686502B1Compounds and methods for treatment of asthma, allergy and inflammatory disordersUCB SA·Filed 2003·Granted Feb 3, 2004·10 cites·1 claims
- 1179US10966986B2Compounds, compositions and methods for cancer patient stratification and cancer treatmentBayer Pharma AG·Filed 2017·Granted Apr 6, 2021·1 cites·8 claims
- 1278US10106502B2Direct inhibitors of Keap1-Nrf2 interaction as antioxidant inflammation modulatorsUNIV RUTGERS·Filed 2017·Granted Oct 23, 2018·2 cites·11 claims
- 1376US6451801B1Compounds and methods for treatment of asthma, allergy and inflammatory disordersUCB SA·Filed 2000·Granted Sep 17, 2002·9 cites·22 claims
- 1474US12053476B2Compounds, compositions and methods for cancer patient stratification and cancer treatmentBayer Pharma AG·Filed 2021·Granted Aug 6, 2024·0 cites·6 claims
- 1574US11096934B2Compounds and methods useful for treating or preventing hematological cancersBROAD INST INC·Filed 2016·Granted Aug 24, 2021·1 cites·10 claims
- 1674US2024182452A16-phenyl-4,5-dihydropyridazin-3(2h)-one derivatives as pde3a and pde3b inhibitors for treating cancerBAYER AG·Filed 2023·Application pending·0 cites
- 1772US6894059B1Compounds and methods for treatment of asthma, allergy and inflammatory disordersUCB SA·Filed 2000·Granted May 17, 2005·7 cites·11 claims
- 1868US6797713B2Compounds and methods for treatment of asthma, allergy and inflammatory disordersUCB SA·Filed 2002·Granted Sep 28, 2004·3 cites·2 claims
- 1965US12427153B21,2,4-triazin-3(2H)-one compounds for the treatment of hyperproliferative diseasesBAYER AG·Filed 2021·Granted Sep 30, 2025·0 cites·8 claims
- 2062US2024109850A1Covalent PPARG inverse-agonistsBAYER AG·Filed 2023·Application pending·0 cites
- 2160US10301294B2Compounds for the treatment of tuberculosisBROAD INST INC·Filed 2014·Granted May 28, 2019·0 cites·5 claims
- 2260US2025170136A11,2,4-triazin-3(2h)-one compounds for the treatment of hyperproliferative diseasesBAYER AG·Filed 2025·Application pending·0 cites
- 2360US2022016106A1Compounds and methods useful for treating or preventing hematological cancersBROAD INST INC·Filed 2021·Application pending·0 cites
- 2457US2020140425A1Compounds for the treatment of tuberculosisBROAD INST INC·Filed 2019·Application pending·0 cites
- 2556US9951055B2Thiazole-based inhibitors of scavenger receptor BIBROAD INST INC·Filed 2013·Granted Apr 24, 2018·0 cites·10 claims
- 2655US11897867B26-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives as PDE3A and PDE3B inhibitors for treating cancerBAYER AG·Filed 2018·Granted Feb 13, 2024·0 cites·3 claims
- 2752US2004048875A1Compounds and methods for treatment of asthma, allergy and inflammatory disordersUCB SA·Filed 2003·Application pending·0 cites
- 2850US2014256767A1Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulatorsUNIV RUTGERS·Filed 2012·Application pending·0 cites
- 2945US2018244629A1Compounds And Compositions For The Treatment Of CancerBROAD INST INC·Filed 2018·Application pending·0 cites
- 3043US2010093716A1Therapeutic methods using wrn binding moleculesUNIV BOSTON·Filed 2007·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Timothy A. Lewis files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →